
Featured News: Stalicla licensing deal
Evgen Pharma has licensed the global rights for lead asset SFX‐01 in neurodevelopmental disorders and schizophrenia to Stalicla
Read More
October 10, 2022
Filter by:
Regulatory News
Media Coverage
Videos
Date
Title
Download
Date
Title
Download